...

Moderna analysis: Those vaccinated last year twice more likely to get COVID-19 than those jabbed recently




Moderna Inc. has released a set of data which suggested its COVID-19 vaccine is effective in preventing serious health issues or death from "variants of concern" but admitting that efficacy decreases over time, such that those who received the vaccine last year were twice more likely to contract a breakthrough case of the coronavirus disease.

According to the data, which Moderna released Wednesday, a "study shows lower risk of breakthrough infection in participants vaccinated more recently (median 8 months after first dose) than participants vaccinated last year (median 13 months after first dose)."

COVID-19 KILLS AMERICANS AT A RATE OF 1 IN 500, DATA SHOWS

A Moderna trial conducted over the summer, labeled Phase 3 COVE Study, revealed that "88 breakthrough cases of COVID-19 occurred in the more recently vaccinated group (49.0 cases per 1000 person-years) compared to 162 cases in the group vaccinated last year (77.1 cases per 1000 person-years)."

Across both groups, Moderna highlighted that "only 19 severe cases were observed." While there was a "numerical trend toward a lower rate of severe cases in the groups vaccinated more recently." Moderna insisted that the number of cases was low enough that the trend was "not significant."

The research found that those who were vaccinated earlier on had a 50% higher rate of symptomatic breakthrough cases during the months of July and August compared to those who had received the vaccination later.

In a statement issued along with the data, Moderna CEO Stéphane Bancel insisted that the data "supports the need for a booster" shot.

"It is promising to see clinical and real-world evidence adding to the growing body of data on the effectiveness of the Moderna COVID-19 vaccine," Bancel said of the unpublished analysis. "The increased risk of breakthrough infections in COVE study participants who were vaccinated last year compared to more recently illustrates the impact of waning immunity and supports the need for a booster to maintain high levels of protection.

Moderna has also requested authorization from the U.S. Food and Drug Administration for a third-dose booster shot, which will be one-half the dose of its existing vaccine.

COMMENTS

More Related News

African effort to replicate mRNA vaccine targets disparities
African effort to replicate mRNA vaccine targets disparities

In a pair of Cape Town warehouses converted into a maze of airlocked sterile rooms, young scientists are assembling and calibrating the equipment needed to reverse engineer a coronavirus vaccine that has yet to reach South Africa and most of the world's poorest people. It's a last resort effort to make doses for people going without, and the intellectual property implications are still murky. "We are doing this for Africa at this moment, and that drives us," said Emile Hendricks, a 22-year-old biotechnologist for Afrigen Biologics and Vaccines, the company trying to reproduce the Moderna jab.

U.S. Pharmacies and States Face New Challenges on Booster Rollout
U.S. Pharmacies and States Face New Challenges on Booster Rollout

Now that federal regulators have cleared booster shots of all three coronavirus vaccines in use in the United States, state health authorities and pharmacies have begun rolling out plans to get even more shots in arms. Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, on Thursday recommended Moderna and Johnson & Johnson boosters for tens of millions of Americans, a move that came nearly a month after many Pfizer-BioNTech recipients were cleared for boosters of t

Walgreens U.S. stores start administering Moderna, J&J COVID-19 booster
Walgreens U.S. stores start administering Moderna, J&J COVID-19 booster
  • US
  • 2021-10-22 13:46:51Z

The Centers for Disease Control and Prevention (CDC) on Thursday said Americans can choose a different shot from their original inoculation as a booster...

CDC advisory panel clears the way for J&J, Moderna and mix-and-match COVID boosters
CDC advisory panel clears the way for J&J, Moderna and mix-and-match COVID boosters

Quick approval by the CDC director is expected, allowing J&J, Moderna and mix-and-match boosters to be given within days.

Moderna and Johnson & Johnson booster shots greenlighted by CDC
Moderna and Johnson & Johnson booster shots greenlighted by CDC

Up to 99 million Americans are now eligible for an additional dose.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Latin America